Preparation, Biosafety, and Cytotoxicity Studies of a Newly Tumor-Microenvironment-Responsive Biodegradable Mesoporous Silica Nanosystem Based on Multimodal and Synergistic Treatment.

Abstract

Patients with triple negative breast cancer (TNBC) often suffer relapse, and clinical improvements offered by radiotherapy and chemotherapy are modest. Although targeted therapy and immunotherapy have been a topic of significant research in recent years, scientific developments have not yet translated to significant improvements for patients with TNBC. In view of these current clinical treatment shortcomings, we designed a silica nanosystem (SNS) with Nano-Ag as the core and a complex of MnO2 and doxorubicin (Dox) as the surrounding mesoporous silica shell. This system was coated with anti-PD-L1 to target the PD-L1 receptor, which is highly expressed on the surface of tumor cells. MnO2 itself has been shown to act as chemodynamic therapy (CDT), and Dox is cytotoxic. Thus, the full SNS system presents a multimodal, potentially synergistic strategy for the treatment of TNBC. Given potential interest in the clinical translation of SNS, the biological safety and antitumor activity of SNS were evaluated in a series of studies that included physicochemical characterization, particle stability, blood compatibility, and cytotoxicity. We found that the particle size and zeta potential of SNS were 94.6 nm and -22.1 mV, respectively. Ultraviolet spectrum analysis showed that Nano-Ag, Dox, and MnO2 were successfully loaded into SNS, and the drug loading ratio of Dox was about 10.2%. Stability studies found that the particle size of SNS did not change in different solutions. Hemolysis tests showed that SNS, at levels far exceeding the anticipated physiologic concentrations, did not induce red blood cell lysis. Further in vitro and in vivo experiments found that SNS did not activate platelets or cause coagulopathy and had no significant effects on the total number of blood cells or hepatorenal function. Cytotoxicity experiments suggested that SNS significantly inhibited the growth of tumor cells by damaging cell membranes, increasing intracellular ROS levels, inhibiting the release of TGF-β1 cytokines by macrophages, and inhibiting intracellular protein synthesis. In general, SNS appeared to have favorable biosafety and antitumor effects and may represent an attractive new therapeutic approach for the treatment of TNBC.

• Authors: Zelai He, Huijun Zhang, Hongwei Li, Yanyan Wang, Jing Qian, Xixi Cai, Li Sun, Jingwen Huang
• Journal: Oxidative medicine and cellular longevity (Oxid Med Cell Longev) Vol. 2020 Pg. 7152173 ( 2020) ISSN: 1942-0994 [Electronic] United States
• PMID: 33488930 (Publication Type: Journal Article)
• Copyright: Copyright © 2020 Zelai He et al.

Chemical References

• Antibiotics, Antineoplastic
• Drug Carriers
• Manganese Compounds
• Silicon Dioxide
• Doxorubicin

Topics

• Animals
• Antibiotics, Antineoplastic (pharmacology)
• Apoptosis
• Cell Survival
• Doxorubicin (pharmacology)
• Drug Carriers (chemistry)
• Drug Delivery Systems
• Drug Synergism
• Hemolysis (drug effects)
• Humans
• Male
• Manganese Compounds (chemistry)
• Nanoparticles (administration & dosage, chemistry)
• Rats
• Rats, Sprague-Dawley
• Silicon Dioxide (chemistry)
• Triple Negative Breast Neoplasms (drug therapy, metabolism, pathology)
• Tumor Cells, Cultured
• Tumor Microenvironment